Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$17.99
+0.9%
$18.14
$16.10
$42.47
$2.26B0.672.35 million shs891,120 shs
Insmed, Inc. stock logo
INSM
Insmed
$98.50
+0.3%
$80.30
$60.40
$106.83
$18.69B0.92.31 million shs1.76 million shs
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
$35.35
-1.6%
$32.53
$27.34
$60.87
$6.50B0.191.37 million shs604,100 shs
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
$24.65
-3.4%
$12.71
$6.48
$37.38
$305.83M0.94476,131 shs994,109 shs
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
$76.01
$75.83
$23.77
$82.20
$3.81B-0.181.14 million shs4,322 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
+0.93%-2.26%-4.44%-9.94%-49.21%
Insmed, Inc. stock logo
INSM
Insmed
+0.26%-3.18%+34.78%+42.38%+58.87%
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
-1.56%+5.59%+24.34%+10.43%-23.00%
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-3.45%-16.95%+119.26%+197.76%+26.41%
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
4.4471 of 5 stars
4.31.00.04.42.02.50.6
Insmed, Inc. stock logo
INSM
Insmed
4.1609 of 5 stars
2.54.00.04.33.41.70.6
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
3.2781 of 5 stars
4.51.00.00.03.11.70.6
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
4.6704 of 5 stars
3.55.00.04.23.72.50.0
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
2.62
Moderate Buy$39.79121.24% Upside
Insmed, Inc. stock logo
INSM
Insmed
3.00
Buy$106.808.43% Upside
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
2.91
Moderate Buy$72.60105.37% Upside
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
3.00
Buy$84.17241.45% Upside
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest INSM, LEGN, TPTX, NKTR, and APLS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/2/2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$25.00 ➝ $26.00
7/2/2025
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$60.00 ➝ $54.00
6/24/2025
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy$60.00 ➝ $100.00
6/24/2025
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$120.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$100.00 ➝ $112.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$96.00 ➝ $110.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$99.00 ➝ $106.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$90.00 ➝ $102.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$107.00 ➝ $119.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$94.00 ➝ $109.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$90.00 ➝ $120.00
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
$781.37M2.89N/AN/A$1.84 per share9.77
Insmed, Inc. stock logo
INSM
Insmed
$381.03M49.04N/AN/A$1.60 per share61.56
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
$627.24M10.36N/AN/A$5.70 per share6.20
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
$87.25M3.51N/AN/A$4.94 per share4.99
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
$30.83M123.46N/AN/A$15.84 per share4.80
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
-$197.88M-$1.79N/AN/AN/A-28.83%-99.19%-25.35%7/30/2025 (Estimated)
Insmed, Inc. stock logo
INSM
Insmed
-$913.77M-$5.95N/AN/AN/A-265.93%-446.98%-52.70%8/6/2025 (Estimated)
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
-$177.03M-$0.59N/AN/AN/A-29.95%-21.19%-13.47%8/8/2025 (Estimated)
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-$118.96M-$9.60N/AN/AN/A-152.49%-329.54%-55.24%8/6/2025 (Estimated)
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
-$236.55M-$6.90N/AN/AN/AN/A-37.45%-35.62%N/A

Latest INSM, LEGN, TPTX, NKTR, and APLS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
-$0.40-$0.07+$0.33-$0.27$190.83 million$195.05 million
5/8/2025Q1 2025
Insmed, Inc. stock logo
INSM
Insmed
-$1.36-$1.42-$0.06-$1.42$91.63 million$92.82 million
5/8/2025Q1 2025
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
-$2.70-$3.30-$0.60-$0.24$15.61 million$10.46 million
5/7/2025Q1 2025
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
-$0.36-$0.74-$0.38-$0.74$197.61 million$149.90 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
N/AN/AN/AN/AN/A
Insmed, Inc. stock logo
INSM
Insmed
N/AN/AN/AN/AN/A
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
N/AN/AN/AN/AN/A
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
N/AN/AN/AN/AN/A
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
2.76
4.08
3.62
Insmed, Inc. stock logo
INSM
Insmed
11.38
5.86
5.44
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
0.30
5.20
5.07
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
N/A
3.24
3.24
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
N/A
16.83
16.83

Institutional Ownership

CompanyInstitutional Ownership
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
96.29%
Insmed, Inc. stock logo
INSM
Insmed
N/A
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
70.89%
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
75.88%
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
90.33%
CompanyEmployeesShares OutstandingFree FloatOptionable
Apellis Pharmaceuticals, Inc. stock logo
APLS
Apellis Pharmaceuticals
770125.68 million117.51 millionOptionable
Insmed, Inc. stock logo
INSM
Insmed
1,271189.71 million184.02 millionOptionable
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
2,609183.76 million183.73 millionOptionable
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
22012.41 million11.76 millionOptionable
Turning Point Therapeutics, Inc. stock logo
TPTX
Turning Point Therapeutics
25050.07 million45.77 millionNot Optionable

Recent News About These Companies

Turning Point of Tampa Now In-Network with Blue Cross Blue Shield Insurance
Glass System in Turning Point Residence
Turning Point Brands Inc.
Alzheimer’s: A Turning Point?
Turning Point Brands Inc (TPB)
Cormorant Asset Management, LP's Net Worth
Solving quadratic equations - Edexcel
BMS bet looking good as Augtyro approved in ROS1-positive NSCLC
A Turning Point for Japan-US Climate Cooperation?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Apellis Pharmaceuticals stock logo

Apellis Pharmaceuticals NASDAQ:APLS

$17.98 +0.17 (+0.93%)
Closing price 07/3/2025 03:48 PM Eastern
Extended Trading
$17.93 -0.05 (-0.31%)
As of 07/3/2025 04:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Insmed stock logo

Insmed NASDAQ:INSM

$98.50 +0.26 (+0.26%)
Closing price 07/3/2025 03:07 PM Eastern
Extended Trading
$98.50 0.00 (0.00%)
As of 07/3/2025 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Legend Biotech stock logo

Legend Biotech NASDAQ:LEGN

$35.35 -0.56 (-1.56%)
Closing price 07/3/2025 02:47 PM Eastern
Extended Trading
$35.35 0.00 (0.00%)
As of 07/3/2025 04:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Nektar Therapeutics stock logo

Nektar Therapeutics NASDAQ:NKTR

$24.65 -0.88 (-3.45%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$24.72 +0.08 (+0.30%)
As of 07/3/2025 04:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Turning Point Therapeutics stock logo

Turning Point Therapeutics NASDAQ:TPTX

Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California.